Loading...
In October 2025, the U.S. Food and Drug Administration approved the use of tezepelumab (Tezspire) as add-on maintenance therapy for patients 12 years and older with chronic rhinosinusitis with nasal polyps that is poorly controlled.
Chronic rhinosinusitis with nasal polyps is typically treated with daily saline rinses and nasal steroids, but a substantial proportion of patients require surgery, followed by biologic therapy if symptoms recur. Approved biologics in this setting include omalizumab, dupilumab, mepolizumab, and now tezepelumab, which is also approved for severe asthma.
In the trial leading to tezepelumab’s approval, 203 patients with severe chronic rhinosinusitis with nasal polyps received monthly subcutaneou…